Custom Search

Topotecan News

BioNumerik begins Phase III ovarian cancer trials on new drug

BioNumerik Pharmaceuticals Inc. on Thursday said the first patient has begun treatment in a global Phase III clinical trial of BioNumerik's anticancer drug candidate, known as Karenitecin, in advanced ovarian cancer patients.

GlaxoSmithKline gets EMEA positive opinion for Hycamtin

GlaxoSmithKline, or GSK, said Monday that oral Hycamtin (topotecan hard capsules) has received a positive opinion from the European Medicines Agency (EMEA) recommending marketing authorisation.

Hycamtin® Improves Survival in Patients with Relapsed Small Cell Lung Cancer

According to the results of a study published in the Journal of Clinical Oncology, patients with relapsed small cell lung cancer survived longer if they were treated with the oral chemotherapy drug Hycamtin® (topotecan) than if...

Hycamtin(R) (Topotecan HCl) Indication Expanded To Include Treatment of Cervical Cancer in Combination With Chemotherapy

Of more than 40 regimens investigated1 Hycamtin® is the first to provide additional survival benefit beyond the current standard treatment

Committee for Medicinal Products for Human Use Post-authorisation Summary of Positive Opinion for Hycamtin

On 18 October 2006 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion to recommend the variation to the terms of the marketing authorisation for the medicinal product Hycamtin. The Marketing...

Displaying results 1 to 5 out of 16





Next >

Use of this site is subject to the following terms of use